Eos SENOLYTIX

Investors · 1

RA

Rapha Capital Management, LLCSurfsidevia Kevin M. Slawin · inferred

DI

Diabetes Prevention Program4 shared keywords

PH

Phoenix SENOLYTIX4 shared keywordsPhoenix SENOLYTIX is a longevity biotech developing controllable gene therapies that target the biological mechanisms of aging, based on its ApoptiCIDe-CE and ApoptiCIDe-RGT platforms and a proprietary cell-elimination switch triggered by a reformulated small molecule. Its programs aim to eliminate senescent cells and adipocytes and to regulate gene-therapy-delivered proteins for aging-related disorders and cancer.

MA

Mapquest3 shared keywordsProvider of geographical information systems and services; acquired by America Online.

LO

Longevity3 shared keywordsLongevity.technology publishes news and insights on longevity science, investment, and innovation, and offers a data platform (DLT) that tracks companies, signals, and trends across the global longevity landscape.

CE

Cenegenics3 shared keywords

Companies competing with Eos SENOLYTIX for the same Google search keywords, organic and paid, via search-intersection analysis.

▶$750KraisedJun 2026 · 2 investors · Pharmaceuticals

Rule 506(b)

Pulmatrix to acquire Eos SENOLYTIX in $19M anti-aging deal By Investing.cominvesting.com · Mar 2026Pulmatrix Announces Q1 2026 Financial Results and Merger Agreement with Eos SENOLYTIX – Minichartminichart.com.sg · May 2026

Officers, directors & promoters on the filing

• Jerold WinogradDirector
• Frank Bartlett McGuyerDirector
• Kevin Mark SlawinExecutive Officer, Director

Offering amount

$25M

Amount sold

$750K

Minimum investment

$250K

First sale

Jun 2026

Incorporated

Corporation, Delaware, 2024

Federal exemptions

06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.